Athena Athena

X
[{"orgOrder":0,"company":"SarcoMed","sponsor":"Protalix BioTherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Protalix BioTherapeutics Inks Non-Binding Term Sheet with SarcoMed USA to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"}]

Find Clinical Drug Pipeline Developments & Deals by SarcoMed

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The arrangement, if consummated, would relate to the development and commercialization of PRX–110, or alidornase alfa, for the treatment of Pulmonary Sarcoidosis and related diseases.

            Lead Product(s): Alidornase alfa

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PRX–110

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Protalix BioTherapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement July 23, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY